Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Moderna, Inc. (MRNA) vs SentinelOne Inc. Class A Common Stock (S) Price & Performance

Moderna, Inc.Trade
SentinelOne Inc. Class A Common StockTrade

Price performance (Past 24H)

Key statistics

Moderna, Inc. vs SentinelOne Inc. Class A Common Stock — how do they compare? Moderna, Inc. trades at $195.54 (market cap $78.65B), while SentinelOne Inc. Class A Common Stock trades at $25.6 (market cap $8.84B). The key difference: Moderna, Inc. is far larger — about 8.9× SentinelOne Inc. Class A Common Stock's market cap, and Moderna, Inc. is more actively traded (37,373,437 versus 7,515,091). Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and SentinelOne Inc. Class A Common Stock for 0 Days on average.

MRNAS
Market Cap
$78.65B$8.84B
Volume
37,373,4377,515,091
Sector
HealthTechnology
52-Week High
$203.46$25.80
52-Week Low
$22.36$11.94
Typical Hold Time
59 Days0 Days
Enterprise Value
$74.80B$8.23B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Moderna, Inc.

Moderna (MRNA) trades at $196.48, up 4.81% amid Nasdaq-100 inclusion news, though it remains well below the analyst consensus target of $115.70. The stock shows bullish technical momentum with recent earnings beats, but faces fundamental challenges with negative profit margins and declining revenue from pandemic-era highs. The company's cash flow improved in 2025, turning positive for the first time since 2022, while its pipeline, including oncology vaccines, attracts investor interest despite valuation concerns.

Outlook: Near-term momentum from index fund buying and pipeline updates may support the stock, but high valuation multiples and persistent losses pose significant risks. Long-term growth depends on successful commercialization of non-COVID products, with current prices reflecting optimistic scenarios. Investors should weigh the potential of the mRNA platform against execution risks and competitive pressures.

SentinelOne Inc. Class A Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MRNA
29% Buy71% Sell
Avg holding period · 59 Days
S
100% Buy0% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA →

About SentinelOne Inc. Class A Common Stock

SentinelOne provides an AI-powered cybersecurity platform for organizations. Its Singularity platform helps detect, prevent, and respond to threats across endpoints, cloud workloads, identities, and connected devices.

Read more on S →